Brief: Homology Medicines Q3 basic EPS USD -0.57
14/11/2023 21:34
Nov 14 (Reuters) - Homology Medicines Q3 operating expenses USD 31.001 million. * Q3 basic EPS USD -0.57 * Q3 income from operations USD -31.001 million * Q3 pretax profit USD -29.578 million * Q3 net income USD -32.954 million
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview